Sector News

After years on the slide, things are looking up in biopharma R&D, report says

August 4, 2015
Life sciences
Whether looking at Phase III success, drug launches or product sales, biopharma is hitting its stride in R&D, according to new analysis from Thomson Reuters. And, as the industry evolves its approach to research and regulators speed up the review process, the latest upswing could be a sign of better days ahead for drug developers.
 
Last year was a banner campaign for the world’s drugmakers, per Thomson Reuters’ latest CMR International factbook. The FDA approved 41 novel candidates–the most in more than a decade–in a year with 44 filings, suggesting a 93% success rate for applicants. That led to 46 drug launches in the developed world, a 17-year high, and 2014 saw global pharma sales cross $1 trillion for the first time, according to the report.
 
And while it’s entirely possible 2014 is an outlier propped up by major new products in hepatitis C and oncology, Thomson Reuters points to some upstream factors suggesting biopharma R&D may have turned a corner.
 
Across the board, early-stage activity has declined while Phase III work has increased, a trend the report sees as evidence that biopharmas have learned to kill low-probability projects in Phase I before they become costly failures in larger trials. And that has had an effect on success rates: The number of terminated Phase III trials has steadily declined over the last 6 years, according to Thomson Reuters.
 
And while those trends point to biopharma learning the lessons of late-stage failures past, they also reflect the ongoing specialization of drug R&D, the report notes. The industry is increasingly seeing the benefit of focusing on rare diseases and unmet needs among small patient populations, as trials for such indications can be done speedily and with fewer volunteers, and global regulators give priority attention to niche medicines.
 
By Damian Garde
 

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach